Skip to main content
Premium Trial:

Request an Annual Quote

This Week in BMC Cancer: Aug 8, 2011


In BMC Cancer this week, researchers in South Korea examine the prognostic significance of CD44 expression in resected non-small-cell lung cancer. The team analyzed CD44 protein expression in tissue samples from 159 patients with resected non-small-cell lung cancer — 82 with adenocarcinoma and 77 with squamous cell carcinoma. It found that high CD44 expression was detected more often in lung cancer patients with squamous cell carcinoma than in those with adenocarcinoma. "Additionally, high CD44s expression was significant correlated with more advanced regional lymph node metastasis," the authors write. "High CD44s expression was a negative prognostic marker with significance in patients with resected non-small-cell lung cancer, particularly those with adenocarcinoma histology, and was independent of tumor stage."

Also in BMC Cancer this week, another team of South Korean researchers elucidate the involvement of Cox2 in the metastatic potential of chemotherapy-resistant breast cancer cells. The team generated a doxorubicin-resistant MCF-7 breast cancer cell line, and studied its metastatic activities. The researchers found that these chemo-resistant cells became invasive with increased expression of EGFR and Cox2. Inhibition of the Cox2, PI3K, or MAPK pathways inhibited the invasive activities of the cell lines, the authors write, adding that Cox2 could be an important target for "chemosensitization and inhibition of metastasis" in chemotherapy-resistant breast cancers.

And finally in BMC Cancer this week, researchers in India say that a novel HIF-1alpha inhibitor also modulates the PI3K pathway and inhibits the growth of prostate cancer cells. The compound, P3155, suppresses HIF-1alpha expression, as well as the PI3K/Akt pathway, and abrogated expression of HIF-1 through VEGF. "P3155 in combination with HIF-1alpha siRNA showed significant synergistic effect," the authors write. "In addition, it demonstrated significant in vivo efficacy and antiangiogenic potential in prostate cancer cell lines."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.